Showing posts with label HER2. Show all posts
Showing posts with label HER2. Show all posts

Saturday, March 7, 2015

New Study Finds Olive Oil Effective against HER-2 Breast Cancer

New Study Finds Olive Oil Effective against HER-2 Breast Cancer
by Barbara L. Minton

(NaturalNews) Olive oil, that magical elixir from the Mediterranean, has long been known to confer many health benefits. It is one reason people who eat the Mediterranean diet live such long, healthy and happy lives. Researchers are busy scientifically documenting these benefits including recent reports on the ability of olive oil to prevent heart disease and colon cancer. The latest study shows that olive oil is effective against HER-2 positive breast cancer, a form of breast cancer for which the medical establishment offers little in the way of tolerable treatment.

Research shows polyphenols from extra virgin olive oil inhibit HER-2 activity

The December, 8 issue of the journal BMC Cancer reports researchers hypothesizing that the effects of the olive oil rich Mediterranean diet on breast cancer risk might be underestimated when it comes to HER-2 breast carcinomas. They investigated the anti HER-2 effects of phenolic fractions directly extracted from commercial extra virgin olive oil (EVOO) in cultured human breast cancer cell lines. They tested for the ability to kill both HER-2 positive and negative tumors. The effects of the EVOO fractions on the expression and activation status of HER-2 oncoprotein were evaluated.

They found that all the major EVOO polyphenols (i.e. secoiridoids and lignans) induced strong tumor killing effects by selectively triggering high levels of apoptotic cell death (programmed cell death) in cells over expressing HER-2. The EVOO polyphenols drastically depleted HER-2 protein and reduced autophosphorylation in a dose and time dependent manner. EVOO polyphenols induced HER-2 downregulation regardless of the molecular mechanism contributing to HER-2 overexpression. (i.e. naturally by gene amplification and ectopically driven by a viral promoter).

The researchers concluded that the ability of EVOO derived polyphenols to inhibit HER-2 activity by promoting the degradation of the HER-2 protein itself, together with the fact that humans have safely been ingesting polyphenols from olive oil for as long as they have been consuming olives and olive oil, support the notion that EVOO is an excellent and safe treatment targeting HER-2.

Olive oil has a long history as a healer

The health and therapeutic benefits of olive oil were first mentioned by Hippocrates, who promoted the idea that food was the best and only medicine worth using. Olive oil has contributed to the nutrition and beauty of the Mediterraneans for centuries, where it is used to maintain skin, hair, and muscle suppleness. It is a healer of abrasions, and soother of the sunburned. It has a history of external as well as internal use, and is one reason Mediterranean women have such glowing skin.

Consuming olive oil can help lower LDL cholesterol. It is rich in antioxidants that discourage artery clogging and chronic diseases involving the cardio-vascular system. People who use olive oil regularly and in place of other fats such as hydrogenated fats and vegetable oils have much lower rates of atherosclerosis, diabetes, colon cancer, and asthma.

A prospective study conducted in Florence, Italy and reported in the August, 2007 edition of the British Journal of Nutrition involved 5,611 adults 60 years or older. These adults adhered to a Mediterranean style dietary pattern characterized by high consumption of olive oil, raw vegetables, soups, and poultry. They were found to have a significantly lower rate of death from all causes in both crude and adjusted models. After 6.2 years, those most closely following an olive oil and salad dietary pattern had a 50% reduced risk of overall mortality.

In the same study people who followed another version of the Mediterranean diet based on a pasta and meat dietary pattern characterized by pasta, tomato sauce, red meat, processed meat, added animal fat, white bread and wine showed an overall mortality risk increase.

A study done in Greece and reported in March, 2007 edition of Clinical Cardiology found that relying only on olive oil may cut the risk of coronary heart disease almost in half. The study involved 700 men and 148 women with coronary heart disease along with 1078 matched controls. It looked at diet as well as alcohol intake, physical activity and smoking habits. Use of oils in daily cooking and food preparation was evaluated. After adjusting for a variety of variables, the exclusive use of olive oil was associated with a 47% lower likelihood of coronary heart disease.

People who consume 25 milliliters (about 2 tablespoons) of virgin olive oil daily for one week showed less oxidation of LDL cholesterol and higher blood levels of antioxidant compounds, especially the phenols used in the HER-2 study.

Olive oil is monounsaturated fat

There are three kinds of dietary fats: saturated fat that comes from animals and coconuts; polyunsaturated fat that comes from plants, seeds, nuts, and vegetable oil; and monounsaturated fat that comes from olive and safflower oil. Monounsaturated fats contain no cholesterol. It is not the monounsaturated fat of olive oil that conveys most of its health benefits. Instead, it is the polyphenols of olive oil that produce its remarkable benefits as was seen in the HER-2 study.

Extra virgin olive oil is well worth its cost

While all types of olive oil are sources of monounsaturated fat, extra virgin olive oil, the oil that comes from the first pressing of the olives, contains higher levels of antioxidants, particularly polyphenols and vitamin E, because it is less processed.

Generally olive oil is extracted by pressing or crushing olives. It comes in different varieties depending on the amount of pressing. These include:

Extra virgin oil - considered the best variety. It is extracted without the use of heat, and is considered a cold pressed oil. Because there is no heat or chemicals involved in its processing the flavor remains intact. As it is handled less, it retains more of its natural state.

Virgin oil - from the second pressing. It is like using a tea bag twice. The nutrients and the flavor just are not what they were the first time around.

Pure - oil has undergone some processing and heat during filtering and refining. A little extra virgin olive oil is added to this refined oil, and creates what is considered a lower grade of oil that is frequently sold under the simple term olive oil in the U.S.

Extra light - oil has undergone considerable processing and is valued by some for its lack of flavor. In this processing many nutrients are compromised. It is frequently marketed as light oil to fool you into thinking it is low fat. This type of oil is unregulated by any certification organization and there is no precedent as to what its content should be. Sometimes it has been cut with other vegetable oils.

Using olive oil

Olive oil prefers to hide its beauty. It does best when kept in a cool and dark location, in a tightly sealed bottle. This is why the really good extra virgin oils come in dark glass bottles. Like other oils, olive oil can easily become rancid when exposed to air, light or high temperatures.

The measure of an oils ability to be used in cooking is its smoke point. Once an oil begins to smoke it has lost its integrity and is producing free radicals.

Olive oil is fine for use in cooking at very low temperatures. For cooking at higher temperatures safflower oil or coconut oil are much better choices. Safflower oil, the other monosaturated oil, retains its integrity at temperatures up to 500 degrees, as does coconut oil. The flavor of safflower oil is not as delicate as that of olive oil, but when it is used in cooking other flavors usually blend well with its taste. Olive oil may be added to cooked foods when they have cooled.

Get creative with olive oil

Add olive oil to almost any cooked food after it has cooled. Use it in soups, sauces, beans, stews, and vegetable dishes. Replace vegetable oil in salad dressings and mayonnaise. Any mealtime fat can be replaced by olive oil. Put some in fresh veggie juices and smoothies. Use it in baked potatoes with herbs such asturmeric, cayenne and cumin. Add it to mashed potatoes. Warm green beans, broccoli or spinach and add olive oil and garlic. Coat cooked pasta in it. Olive oil makes a great dip for bread, especially when embellished with some oregano or thyme. Put it on air popped corn along with some sea salt and black pepper.

Use olive oil as a hair conditioner, diaper rash treatment, and skin softener. Rub it on your breasts.

Sources of information about olive oil are:

Olive Oil`s Health Benefits, healingdaily.com.

Olive Oil: Extra Virgin, whfoods.com.

Health Benefits of Olive Oil and the Mediterranean Diet, mediterraneandiet.gr.
s.shtml

Thursday, June 5, 2014

HER2 and other Clinical Trials based on Bad Science or NOT, you cannot tell.




Humans become guinea pigs after animal trials: bad idea based on questionable animal science. Since chemo causes metastasis, and they are going to use another chemo agent, they cause the metastasis and then stop it. KEEP HEALING LOGICAL. Do background checks on the trials, if you can get access to them, before you fall for this type of hype and become a "trial collateral damage".

More often than not, according to one the leading researchers in clinical trials, the animal study is poorly designed, but designed to show what the research needs to show, but it relates POORLY to the human, but is used to attract humans into a trial. BE aware!

http://bit.ly/clinicaltrialflaw
http://bit.ly/CANCERMETABOLIC Animal models do not allow metastasis so the conclusion that a drug is good and shows now metastasis is based on bad science. How would the patient know this? You won't! You don't have access to the data and research methods.

Powerful new way to treat HER2-positive breast cancer validated

Kathy Boltz, PhD
Share this article:
Although HER2-positive breast cancer can be treated with the drug Herceptin, it typically develops resistance within several years. A multi-institutional team has found a means of inhibiting another protein, protein tyrosine phosphatase 1B (PTP1B), whose expression is also upregulated in HER2-positive breast cancer. PTP1B has a critical role in the development of tumors in which HER2 signaling is aberrant.
The breast cancer subtype in question is commonly called "HER2-positive"; it's a subset of the disease affecting about one patient in four, in which tumor cells overexpress the HER2 signaling protein. Because resistance to the drug Herceptin develops within several years in most cases, the prognosis for patients with HER2-positive breast cancer is worse than for those with other subtypes of the disease.
Scientists at Cold Spring Harbor Laboratory (CSHL) in New York, led by Nicholas Tonks, PhD, and their collaborators hope their discovery will lead to the development of a powerful new way of treating an aggressive form of breast cancer. Their research was reported in Nature Chemical Biology (2014; doi:10.1038/nchembio.1528).
Tonks and colleagues found that treating mice modeling HER2-positive breast cancer with the PTP1B inhibitor MSI-1436 (also called trodusquemine), inhibited HER2 protein signaling.
"The result was an extensive inhibition of tumor growth and prevention of metastasis to the lung in HER2-positive animal models of breast cancer," noted Navasona Krishnan, PhD, a postdoctoral investigator in the Tonks lab who performed many of the experiments and is lead author on the paper reporting the results.
Tonks discovered PTP1B some 25 years ago. It is an enzyme, among a "superfamily" of 105 called protein tyrosine phosphatases, that performs the essential biochemical task of removing phosphate groups from amino acids called tyrosines in other proteins. Adding and removing phosphate groups is one of the means by which signals are sent among proteins.
For many years, PTP1B has been a target of interest among drug developers. It is well known to be a negative regulator of insulin, or an antagonist of insulin signaling, and of signaling by leptin, the hormone that helps regulate appetite. Drugs that can block or inhibit the action of PTP1B have great potential in controlling diabetes and obesity. Yet properties of the molecule that involve both its charged active binding site and its shape have stymied potential developers of inhibitory drugs.
The new paper importantly reveals an alternative binding site (called an allosteric site) that does not present the biochemical difficulties that the active, or catalytic, binding site does. This allosteric site is a target of the candidate drug trodusquemine.
Later this year early stage human trials will begin for the drug, a collaboration of CSHL and North Shore-Long Island Jewish Hospital. Tonks and CSHL have interests in a joint venture called DepYmed Inc., in partnership with Ohr Pharmaceutical. The venture seeks to develop trodusquemine and related analogs.